कोशिश गोल्ड - मुक्त

AUSTRALIAN AGED CARE GETS BOOSTER DOSE

BioSpectrum Asia

|

BioSpectrum Asia June 2021

In 2017, there were 3.8 million Australians aged 65 and over (comprising 15 per cent of the total population) —increasing from 319,000 (5 per cent) in 1927 and 1.3 million (9 per cent) in 1977. The number and proportion of older Australians is expected to continue to grow. By 2057, it is projected that there will be 8.8 million older people in Australia (22 per cent of the population); by 2097, 12.8 million people (25 per cent) will be aged 65 and over according to Australian Bureau of Statistics (ABS) 2017. Looking at the growing trend, the government of Australia has a separate ministry for Senior Australians and Aged Care Services and undertaken many steps to support them with respect, care and dignity.

- Narayan Kulkarni

AUSTRALIAN AGED CARE GETS BOOSTER DOSE

The Australian Government has taken an important step to deliver its reforms to aged care by introducing the first legislation in response to the Royal Commission into Aged Care Quality and Safety. The Aged Care and Other Legislation Amendment (Royal Commission Response No. 1) Bill 2021 has been introduced into Parliament on May 27, 2021, and makes necessary changes to current aged care legislation, ahead of the new Aged Care Act planned for 2023.

This bill is the first step in the Government’s five-year, five-pillar, aged care reform plan addressing home care, residential aged care services and sustainability, residential care quality and safety, workforce and governance. The health, safety and wellbeing of senior Australians is of the utmost importance to the government, and is driving its plan for generational change of the aged care sector.

Minister for Health and Aged Care, Greg Hunt, said that the amendments will deliver immediate priority changes around restrictive practices, home care assurance reviews, and repeal the Aged Care Financing Authority. “Regulating the use of restrictive practices, like chemical and physical restraint, is a critical focus for the Australian Government to improve quality and safety of aged care”, Minister Hunt said.

“Addressing concerns raised by the Royal Commission and the independent review into restraint, our amendments will mean from July 1, we will have clearly defined restrictive practices, which align with the definitions used in the disability sector. We are strengthening legislation to ensure that restrictive practices are only used as a last resort, the impact on the care recipient is considered, and consent arrangements are clear,” said Hunt.

BioSpectrum Asia से और कहानियाँ

BioSpectrum Asia

Repligen introduces next-generation chromatography resins

Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, has announced the launch of three new high-performance chromatography resins:

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

Hanahealth by DSS Imagetech launches GERI Time-Lapse Incubator in India

Hanahealth by DSS Imagetech, the authorised partner of Sydney-based Genea Biomedx, has launched the advanced GERI Time-Lapse Incubator pan India. GERI, the nextgeneration Time Lapse embryo culture system from Genea Biomedx, is ideal for IVF clinics, labs adopting digital transformation, centres working toward accreditation, and research-focused fertility groups as it enables them to modernise their processes and improve IVF outcomes.

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

Biotechnology to Drive Next Industrial Revolution: Dr Jitendra Singh

\"Biotechnology will play a defining role in shaping the next industrial revolution and will be a key driver of global and Indian economic growth\", said Dr Jitendra Singh, the Union Minister of State (Independent Charge) for Science and Technology.

time to read

1 mins

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

Cartherics names Dr lan Nisbet as CEO

Australia-based Cartherics, a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women's diseases, with lead programmes in ovarian cancer and endometriosis, has announced the appointment of Dr Ian Nisbet as Chief Executive Officer, as part of a planned leadership transition.

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

Neurophet ropes in Josh Cohen as Head of Americas Business

South Korea-based Neurophet, an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, has appointed Josh Cohen, a veteran executive from leading global medical device companies, as new Head of Americas Business.

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

India's Final Mile to TB Elimination

As the target year 2025 draws to a close, the Government of India has intensified and consolidated nationwide efforts to eliminate tuberculosis (TB) through the TB-Mukt Bharat Abhiyaan, implemented under the National Tuberculosis Elimination Programme (NTEP). India's decision to advance the TB elimination timeline ahead of global targets has driven sustained reforms across detection, treatment, prevention, nutrition support, and community engagement.

time to read

2 mins

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

Korea builds AI-engineered nasal spray antiviral platform

A research team at Korea Advanced Institute of Science and Technology has successfully developed a nasal (intranasal) antiviral platform using artificial intelligence (AI) technology to overcome the existing limitations of interferonlambda treatments, namely, being weak against heat and disappearing quickly from the nasal mucosa.

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

"Industry needs to evolve and invest in ADC payloads with more differentiated mechanisms of action

Antibody drug conjugates (ADCs) are becoming highly valuable in the market, with currently 15 approved ADCs targeting 16 different indications for haematological and solid tumour malignancies. With key components of ADCs, such as mAbs, linkers, payloads, and conjugation technologies, undergoing rapid advancements, a solid foundation has been laid for future research and development in this field, particularly in North America which is the largest market shareholder for ADCs. US recently wrapped up the world's largest & definitive Antibody-Drug Conjugate event, World ADC, held in November 2025, highlighting the development of novel ADCs through key market players, and a surge in patent application filing for ADCs. Dr Allan Jordan, Vice President of Oncology Drug Discovery at Sygnature Discovery, UK spoke in detail with BioSpectrum Asia about the future outlook of ADCs.

time to read

4 mins

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

Cytiva and Fida Biosystems collaborate to improve molecular insight for faster drug discovery

Cytiva, a Danaher company and leader in the life sciences industry, and Fida Biosystems, a Danish company specialising in molecular analysis, have joined forces to expand analytical capabilities for protein research.

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Excellence Awards Highlight Strength and Future of India's Biotechnology Sector

Former Secretary, Department of Biotechnology (DBT), Government of India, Dr Renu Swarup, underscored the importance of recognising excellence across the biotechnology ecosystem while chairing the jury at the BioSpectrum Excellence Awards.

time to read

1 min

BioSpectrum Asia Jan 2026

Translate

Share

-
+

Change font size